Viewing Study NCT01609127


Ignite Creation Date: 2026-03-26 @ 3:20 PM
Ignite Modification Date: 2026-04-01 @ 9:53 PM
Study NCT ID: NCT01609127
Status: UNKNOWN
Last Update Posted: 2012-06-01
First Post: 2012-05-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
Sponsor: Genta Incorporated
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module